Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 1
2007 2
2008 3
2009 3
2010 2
2011 2
2013 2
2014 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G, Bazarbachi A, El-Cheikh J. Amhaz G, et al. Leuk Res Rep. 2022 May 18;17:100325. doi: 10.1016/j.lrr.2022.100325. eCollection 2022. Leuk Res Rep. 2022. PMID: 35663281 Free PMC article.
Also multiple other agents emerged targeting different surface cell antigens like CD52 (alemtuzumab), CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin]), CD80 (galiximab), CD2 (MEDI-507 [siplizumab]), CD30 (SGN-30 and MDX-060 [iratumumab] …
Also multiple other agents emerged targeting different surface cell antigens like CD52 (alemtuzumab), CD22 (unconjugated epratuzumab and cal …
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC. Tai YT, et al. Cancer Res. 2004 Apr 15;64(8):2846-52. doi: 10.1158/0008-5472.can-03-3630. Cancer Res. 2004. PMID: 15087402 Retracted.
SGN-40 (0.01-100 micro g/ml) induces modest cytotoxicity in MM cell lines and patient MM cells. ...SGN-40 treatment also induces a down-regulation of CD40 dependent on an endocytic pathway. ...
SGN-40 (0.01-100 micro g/ml) induces modest cytotoxicity in MM cell lines and patient MM cells. ...SGN-40 treatm
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS. Law CL, et al. Cancer Res. 2005 Sep 15;65(18):8331-8. doi: 10.1158/0008-5472.CAN-05-0095. Cancer Res. 2005. PMID: 16166310
SGN-40 is a humanized IgG1 antihuman CD40 that is currently in a phase I clinical trial for the treatment of multiple myeloma. ...Recombinant SGN-40 showed high affinity, Kd of approximately 1 nmol/L, and specific binding to CD40. ...
SGN-40 is a humanized IgG1 antihuman CD40 that is currently in a phase I clinical trial for the treatment of multiple myeloma.
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Tai YT, et al. Cancer Res. 2005 Dec 15;65(24):11712-20. doi: 10.1158/0008-5472.CAN-05-1657. Cancer Res. 2005. PMID: 16357183
Importantly, pretreatment with lenalidomide or lenalidomide and SGN-40 markedly enhanced NK-cell-mediated lysis of autologous patient MM cells triggered by SGN-40. ...Finally, pretreatment of both effector and target MM cells with lenalidomide markedly …
Importantly, pretreatment with lenalidomide or lenalidomide and SGN-40 markedly enhanced NK-cell-mediated lysis of autologous …
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS. Kelley SK, et al. Br J Pharmacol. 2006 Aug;148(8):1116-23. doi: 10.1038/sj.bjp.0706828. Epub 2006 Jul 10. Br J Pharmacol. 2006. PMID: 16847437 Free PMC article.
SGN-40 exhibited nearly 100% bioavailability in mice and it cleared faster when given at a low dose. ...Data presented in this report suggest that SGN-40 is active in in vivo, and based upon interspecies scaling, SGN-40 clearance in human
SGN-40 exhibited nearly 100% bioavailability in mice and it cleared faster when given at a low dose. ...Data presented in this
Targeting CD40 in Waldenström's macroglobulinemia.
Lee M, Advani R. Lee M, et al. Clin Lymphoma Myeloma. 2009 Mar;9(1):87-9. doi: 10.3816/CLM.2009.n.023. Clin Lymphoma Myeloma. 2009. PMID: 19362983 Review.
In Waldenstrom's macroglobulinemia (WM), CD40 expression is a common feature of bone marrow infiltrating lymphoplasmacytic cells, and preclinical evidence suggests that CD40 signaling is functionally important for WM growth and survival. Two antibodies targeting CD40 (SGN- …
In Waldenstrom's macroglobulinemia (WM), CD40 expression is a common feature of bone marrow infiltrating lymphoplasmacytic cells, and precli …
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. Lapalombella R, et al. Br J Haematol. 2009 Mar;144(6):848-55. doi: 10.1111/j.1365-2141.2008.07548.x. Epub 2009 Jan 12. Br J Haematol. 2009. PMID: 19183192 Free PMC article.
SGN-40 also mediated antibody-dependent cellular cytotoxicity (ADCC) predominantly through natural killer (NK) cells. ...These data together provide justification for clinical trials of SGN-40 and lenalidomide in combination for CLL therapy....
SGN-40 also mediated antibody-dependent cellular cytotoxicity (ADCC) predominantly through natural killer (NK) cells. ...These
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP. Oflazoglu E, et al. Br J Cancer. 2009 Jan 13;100(1):113-7. doi: 10.1038/sj.bjc.6604812. Epub 2008 Dec 9. Br J Cancer. 2009. PMID: 19066610 Free PMC article.
SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling cells and by cell-mediated cytotoxicity. Here we show antibody-dependent cellular phagocytosis (ADCP) by macrophages to contribute signific
SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling
21 results